Emanuela Anna Pesce

Surgical Management of Multiple Myeloma and Plasmocytoma of the Spine

Gisberto Evangelisti, Emanuela Anna Pesce, Rajiv B. Gala, Stefano Bandiera et autres

Corpectomy is an important treatment option for various cervical pathologies and evaluation of treatment success on imaging can be even more difficult than for interbody fusion.

it, in (code pays fourni par la source)

Incidence and outcomes of rare T cell lymphomas from the T Cell Project: hepatosplenic, enteropathy associated and peripheral gamma delta T cell lymphomas

Francine M. Foss, Steven M. Horwitz, Monica Civallero, Monica Bellei et autres

The T Cell Project was the largest prospective trial to explore the incidence, treatment patterns, and outcomes for T cell lymphomas. The rare subtypes of T cell lymphomas, including hepatosplenic T cell lymphoma (HSTCL), enteropathy associated T cell lymphoma (EATL), and peripheral …

us, it, kr, cl, es, il, gb, br, ua (code pays fourni par la source)

Rituximab plus bendamustine as front-line treatment in frail elderly (>70 years) patients with diffuse large B-cell non-Hodgkin lymphoma: a phase II multicenter study of the Fondazione Italiana Linfomi

Sergio Storti, Michele Spina, Emanuela Anna Pesce, Flavia Salvi et autres

We conducted a phase II study to assess activity and safety profile of bendamustine and rituximab in elderly patients with untreated diffuse large B-cell lymphoma (DLBCL) who were prospectively defined as frail using a simplified version of the Comprehensive Geriatric Assessment (CGA). …

it (code pays fourni par la source)

The outcome of peripheral T-cell lymphoma patients failing first-line therapy: a report from the prospective, International T-Cell Project

Monica Bellei, Francine M. Foss, Andrei R. Shustov, Steven M. Horwitz et autres

This analysis explored factors influencing survival of patients with primary refractory and relapsed peripheral T-cell lymphomas enrolled in the prospective International T-cell Project. We analyzed data from 1020 patients with newly diagnosed disease, enrolled between September 2006 and December 2015. Out of …

it, us, kr, cl, es, il, gb, br, ua (code pays fourni par la source)

Nonpegylated liposomal doxorubicin combination regimen in patients with diffuse large B‐cell lymphoma and cardiac comorbidity. Results of the HEART01 phase II trial conducted by the Fondazione Italiana Linfomi

Stefano Luminari, E Viel, Andrés J.M. Ferreri, Francesco Zaja et autres

The purpose of this phase 2, multicenter study was to determine the activity and safety of nonpegylated liposomal doxorubicin as part of "R-COMP" combination in patients with diffuse large B-cell lymphoma and coexisting cardiac disorders. The study was conducted using a Bayesian …

it, my (code pays fourni par la source)

The Outcome of Patients with Primary Refractory or Relapsed Peripheral T-Cell Lymphoma: Analysis of 1020 Cases Registered in the Prospective T-Cell Project

Monica Bellei, Francine M. Foss, Steven M. Horwitz, Luigi Marcheselli et autres

Abstract Introduction: Current treatment strategies for mature or peripheral T-cell lymphomas (PTCL) patients (pts) are largely unsatisfactory. In particular, pts failing first line therapy are expected to have a dismal outcome. The purpose of the present analysis was to analyze clinical features …

it, us, kr, cl, es, il, gb, br, ua (code pays fourni par la source)

Brentuximab vedotin followed by ABVD +/− radiotherapy in patients with previously untreated Hodgkin lymphoma: final results of a pilot phase II study

Massimo Federico, Stefano Luminari, Cinzia Pellegrini, Francesco Merli et autres

Brentuximab vedotin followed by ABVD +/radiotherapy in patients with previously untreated Hodgkin lymphoma: final results of a pilot phase II study

it (code pays fourni par la source)

The Value and Relevance of the T Cell Lymphoma Registries and International Collaborations: the Case of COMPLETE and the T-Cell Project

Monica Bellei, Chadi Nabhan, Emanuela Anna Pesce, Luana Conte et autres

it, us (code pays fourni par la source)

Low toxicity profile of the combination of bendamustine plus rituximab in elderly frail patients with newly Diagnosed Diffuse Large B-Cell Lymphoma (DLBCL)

Michele Spina, Stefano Luminari, Flavia Salvi, Francesco Passamonti et autres

ua, it, gr (code pays fourni par la source)

Brentuximab Vedotin Followed By ABVD in Patients with Previously Untreated Hodgkin Lymphoma. a Pilot Phase II Study

Pier Luigi Zinzani, Stefano Luminari, Francesco Merli, Emanuela Anna Pesce et autres

Abstract active and well tolerated single agent in the treatment of heavily pretreated Hodgkin lymphoma patients. In this pilot phase II study patients with previously untreated HL underwent sequential regimen consisting in 2 cycles of BV before doxorubicin, bleomycin, vinblastine and dacarbazine …

it (code pays fourni par la source)

Low Toxicity Profile of the Combination of Bendamustine Plus Rituximab (BR) in Elderly FRAIL Patients with Newly Diagnosed DLBCL

Michele Spina, Stefano Luminari, Flavia Salvi, Francesco Passamonti et autres

Abstract Introduction: R-CHOP is the gold standard for the treatment of elderly patients with DLBCL. However, unfit and frail patients frequently do not qualify for CHOP-based chemotherapy. Alternatives are an urgent medical need. Bendamustine plus rituximab (BR) has been established as a …

it (code pays fourni par la source)

A pilot phase II study with brentuximab vedotin followed by ABVD in patients with previously untreated Hodgkin lymphoma: A preliminary report.

Massimo Federico, Emanuela Anna Pesce, Francesco Merli, Stefano Luminari et autres

8507 Background: In the majority of patients with relapsed or refractory Hodgkin Lymphoma (HL) Brentuximab vedotin (BV) has shown significant activity, with a manageable safety profile. We aimed to assess the role of 2 cycles of BV before starting the standard treatment …

it (code pays fourni par la source)